

CI Bio-Revolution Index ETF (formerly CI Bio-Revolution ETF)

TSX TICKER : CDNA



AS AT MARCH 31, 2024

FUND OVERVIEW

The ETF seeks to replicate, to the extent reasonably possible, the performance of a global biotechnology and genomics industry index, net of expenses. Currently, the ETF seeks to replicate the performance of the Solactive Global Genomics Immunology and Medical Revolution CAD Hedged Index (the "Index"). The Index intends to track the performance of companies that have business operations in the global biotechnology and genomics industry using the ARTIS® classification system. The Index hedges foreign currency exposure back to Canadian dollars.

FUND DETAILS

Inception date	February 2022
Total net assets (\$CAD) As at 2024-03-28	\$5.1 million
NAVPS	\$17.2787
Market price	\$17.2900
MER (%) As at 2023-12-31	0.44
Management fee (%)	0.40
Units outstanding As at 2024-04-15	300,000
Asset class	Sector Equity
Currency	CAD
CUSIP	12545U100
Distribution frequency	Quarterly
Last distribution	\$0.0189

Risk rating¹




INVESTOR SUITABILITY

For Those Who:


- Want Exposure To Companies That Are Involved In The Global Biotechnology And Genomics Industry
- Are Investing For The Medium And/Or Long Term
- Can Tolerate Medium To High Risk

PERFORMANCE²

Growth of \$10,000 (since inception date)



Calendar year performance



Average annual compound returns


YTD	1 Mo	3 Mo	6 Mo	1 Y	3 Y	5 Y	10 Y	Inception *
-1.79%	-2.82%	-1.79%	5.56%	-2.67%	-	-	-	-6.03%

*Since inception date

DISTRIBUTION HISTORY³

Payable date	Total
2024-03-21	0.0189
2023-12-20	0.0350
2023-06-23	0.0348
2023-03-24	0.1870

MANAGEMENT TEAM



Lijon Geeverghese

CI Bio-Revolution Index ETF (formerly CI Bio-Revolution ETF)

TSX TICKER : CDNA



AS AT MARCH 31, 2024

PORTFOLIO ALLOCATIONS⁴

Asset allocation	(%)	Sector allocation	(%)	Geographic allocation	(%)
US Equity	73.58	Healthcare	99.54	United States	73.24
International Equity	25.96	Cash and Cash Equivalent	0.41	Switzerland	9.25
Cash and Equivalents	0.41	Other	0.05	Cayman Islands	3.77
Other	0.05			Germany	2.35
				Netherlands	2.13
				United Kingdom	2.02
				Denmark	1.98
				Other	1.94
				Korea, Republic Of	1.74
				France	1.58

TOP HOLDINGS

	Sector	(%)
1. Illumina Inc	Healthcare Equipment	3.35%
2. Beam Therapeutics Inc	Drugs	3.24%
3. Lonza Group AG	Drugs	3.24%
4. Moderna Inc	Drugs	3.19%
5. CRISPR Therapeutics AG	Drugs	3.04%
6. Thermo Fisher Scientific Inc	Healthcare Equipment	3.03%
7. Twist Bioscience Corp	Drugs	2.99%
8. Vertex Pharmaceuticals Inc	Drugs	2.92%
9. AbbVie Inc	Drugs	2.88%
10. Sarepta Therapeutics Inc	Drugs	2.81%
11. Intellia Therapeutics Inc	Drugs	2.75%
12. Agilent Technologies Inc	Healthcare Equipment	2.65%
13. PTC Therapeutics Inc	Drugs	2.57%
14. Natera Inc	Healthcare Equipment	2.51%
15. Bristol-Myers Squibb Co	Drugs	2.37%

Note: This page is not complete without disclaimers on the next page.

Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. [Learn more at ci.com.](#)

¹ The risk level of a fund has been determined in accordance with a standardized risk classification methodology in National Instrument 81-102, that is based on the fund's historical volatility as measured by the 10-year standard deviation of the fund's returns. Where a fund has offered securities to the public for less than 10 years, the standardized methodology requires that the standard deviation of a reference mutual fund or index that reasonably approximates the fund's standard deviation be used to determine the fund's risk rating. Please note that historical performance may not be indicative of future returns and a fund's historical volatility may not be indicative of future volatility.

² Commissions, management fees and expenses all may be associated with an investment in exchange-traded funds (ETFs). You will usually pay brokerage fees to your dealer if you purchase or sell units of an ETF on recognized Canadian exchanges. If the units are purchased or sold on these Canadian exchanges, investors may pay more than the current net asset value when buying units of the ETF and may receive less than the current net asset value when selling them. Please read the prospectus before investing. Important information about an exchange-traded fund is contained in its prospectus. The indicated rates of return are the historical annual compounded total returns net of fees and expenses payable by the fund (except for figures of one year or less, which are simple total returns) including changes in security value and reinvestment of all dividends/distributions and do not take into account sales, redemption, distribution or optional charges or income taxes payable by any securityholder that would have reduced returns. ETFs are not guaranteed; their values change frequently, and past performance may not be repeated.

³ Please refer to the fund's simplified prospectus for distribution information.

⁴ Portfolio allocations will fluctuate over the life of the ETF as the portfolio holdings and market value of each security changes. The portfolio manager(s) may change the portfolio allocations in some or all of the sectors.

The contents are not to be used or construed as investment advice or as an endorsement or recommendation of any entity of security discussed.

Certain statements contained in this communication are based in whole or in part on information provided by third parties and CI has taken reasonable steps to ensure their accuracy.

The rates of return are used only to illustrate the effects of the compound growth rate and are not intended to reflect future values or returns on investment in an investment fund.

The "Growth of \$10,000 invested" chart shows the final value of a hypothetical \$10,000 investment in securities in this class/series of the fund as at the end of the investment period indicated and is not intended to reflect future values or returns on investment in such securities.

Management Expense Ratio ("MER") represents the trailing 12-month management expense ratio, which reflects the cost of running the fund, inclusive of applicable taxes including HST, GST and QST (excluding commissions and other portfolio transaction costs) as a percentage of daily average net asset value the period, including the fund's proportionate share of any underlying fund(s) expenses, if applicable. The MER is reported in each fund's Management Report of Fund Performance ("MRFP"). MRFPs can be found within the Documents tab on ci.com.

The CI Exchange-Traded Funds (ETFs) are managed by CI Global Asset Management, a subsidiary of CI Financial Corp. (TSX: CIX). CI Global Asset Management is a registered business name of CI Investments Inc.

© CI Investments Inc. 2024. All rights reserved.